Bosutinib/Bosutinib Overview of Dosage and Dosage

Bosutinib/Bosutinib (Bosutinib) is a targeted therapy drug, mainly used for newly diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (CP Ph+CML), as well as patients with drug resistance or intolerance to previous treatments. Its indications include patients over 1 year old with chronic phase, accelerated phase (AP) or blast phase (BP) Ph+CML.

In terms of medication, the recommended method of use of bosutinib is to take it orally once a day with a meal. The tablet must be swallowed whole and must not be broken or cut. The specific dosage is as follows:

1. Adult patients:

For newly diagnosedCP Ph+CML patients, the recommended initial dose is 400 mg daily.

For patients with Ph+CML in the chronic, accelerated or blast phaseor those who have developed resistance or intolerance to previous treatments, the recommended initial dose is 500 mg daily.

2. Pediatric patients:

For newly diagnosed CP Ph+CML patients, the recommended dose is 300mg/m².

For patients with CP Ph+CML who are resistant or intolerant to previous treatmentThe recommended dose is 400mg/m².

During the treatment process, if the patient experiences adverse reactions or fails to achieve the expected therapeutic effect, the doctor can adjust the dosage according to the patient's specific condition. For patients who have achieved or maintained a response, consider increasing the dose by 100 mg each time, up to a maximum dose of 600 mg daily.

For patients who are unable to swallow capsules, the contents of the capsules can be mixed with applesauce or yogurt. Here's how: Take out the desired number of capsules and prepare room temperature applesauce or yogurt. Carefully open each capsule, add all the contents into the prepared applesauce or yogurt, and mix thoroughly. The patient should consume the mixture immediately without chewing. It is important to note that the mixture must not be stored for later use. If the patient does not swallow the medication completely, no additional dose is needed and the medication should be resumed the next day.

Through correct usage and dosage, the therapeutic effect of bosutinib can be maximized and the risk of potential adverse reactions can be reduced.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adc84ad5-a04d-4fee-9ba8-91f7abd928e3